Trial Profile
Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs REP 2139 (Primary) ; Entecavir; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors REPLICor
- 06 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2016 According to a Replicor media release, updated clinical data of this study will be presented at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver.
- 10 Apr 2015 According to a REPLICor media release, the updated data from this and another trial will be presented at the 2015 Lancet Viral Hepatitis Conference.